Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin‐deficient mdx mice: proof‐of‐concept study and independent validation of efficacy-Reference-Cited by-同舟云学术

Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin‐deficient mdx mice: proof‐of‐concept study and independent validation of efficacy

Published:2018-01-03 Issue:2 Volume:32 Page:1025-1043
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Capogrosso Roberta Francesca¹,Mantuano Paola¹,Uaesoontrachoon Kitipong²,Cozzoli Anna¹,Giustino Arcangela¹,Dow Todd²,Srinivassane Sadish²,Filipovic Marina²,Bell Christina²,Vandermeulen Jack²,Massari Ada Maria¹,De Bellis Michela¹,Conte Elena¹,Pierno Sabata¹,Camerino Giulia Maria¹,Liantonio Antonella¹,Nagaraju Kanneboyina²³,De Luca Annamaria¹

Affiliation:

1. Pharmacology UnitDepartment of Pharmacy–Drug SciencesUniversity of BariBariItaly

2. Agada Biosciences, IncorporatedHalifaxNova ScotiaCanada

3. Binghamton UniversitySchool of Pharmacy and Pharmaceutical SciencesBinghamtonNew YorkUSA

Funder

Muscular Dystrophy Association

National Institutes of Health

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link